Personalized mRNA Vaccine Improves Melanoma Recurrence Outcomes

Company Merck; Moderna Event Type Phase 3 detailed results Modality Individualized neoantigen mRNA vaccine plus anti-PD-1 Asset Intismeran autogene plus pembrolizumab Target Tumor neoantigens; PD-1 Disease Area Resected high-risk melanoma (stage IIB–IV) Summary Detailed randomized Phase 3 results strengthen the case that individualized neoantigen vaccination…